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Improved synthesis of 3-aryl-isoxazoles as intermediates for novel G-quadruplex binding 
anti-tumor agents 
 
Nicholas R. Natale 
 
 
  As a promising new target for chemotherapy G-quadruplexes (G4) have drawn great 
interest from the scientific community. Current chemotherapeutic agents exhibit broad 
toxicity to patients; G4 has the potential to be selectively targeted by novel 
chemotherapeutic agents that exhibit toxicity specific towards cancer cells. Anthracenyl 
isoxazolyl amides (AIMs) have shown potent anti-tumor activity and have evidence to 
support them as G4 binding molecules. Studies of the AIMs’ unique mechanism of action 
require an efficient synthesis of target molecules. For our system, methods traditionally 
used to synthesize isoxazoles were inefficient and gave poor yields. A critical comparison 
of methods to prepare sterically hindered 3-aryl isoxazoles containing fused aromatic 
rings using the nitrile oxide cycloaddition (NOC) revealed that modification of the 
method of Bode, Hachisu, Matsuura and Suzuki (BHMS), was far superior to that of the 
enamine method. Utilization of either triethyl amine as a base or sodium enolates of 
diketone, ketoester and ketoamide dipolarophiles gave much higher yields as well as 
fewer by-products from the NOC. Here-in is reported the improved synthesis of 3-aryl-
isoxazoles via an adaption of the BHMS method. Included in this report is the 
crystallographic data for Ethyl 3-(10'-bromo-9'-anthracenyl)-5-methyl-4-
isoxazolcarboxylate. As seen in the crystal structure of the chapter 2 title compound the 
isoxazole plane is nearly orthogonal to the plane of the anthracene; which is thought to be 
a necessity for the AIMs to interact with G4. This conformation is ideal for both pi-
stacking with the guanine decks and polar interactions with the phosphate backbone of 
quadruplex DNA. 
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Introduction 
There are many cellular mechanisms by which a cell attempts to maintain the 
crucial balance between proliferation and apoptosis. When these mechanisms fail the cell 
either dies or goes into uncontrolled proliferation which is considered one of the 
“hallmarks of cancer” (Hanahan and Weinberg, 2011). This immortality may be achieved 
by circumventing the natural aging mechanisms. Maintenance of telomeres by telomerase 
plays a crucial role in a cells ability to replicate indefinitely (Kelland, 2007). Small 
molecules that could recognize and bind the telomere would have the potential inhibit 
cancer growth by blocking telomerase from replicating the telomere. One target that may 
allow for small molecules to select for telomeric DNA is the G-quadruplex (G4) (Burge, 
et al., 2006). 
Human DNA can adopt many structures other than that of the classical double-
helix. G-quartets are planar structures formed in guanine-rich regions of DNA and RNA. 
These quartets often stack in sets of three and have been shown to form several three-
dimensional G4 structures in isolated DNA sequences (Neidle, 2012). The presence of 
G4 has also been recently quantified in human cells (Biffi, et al., 2013). Telomeric G4 
has drawn considerable interest as maintenance of the telomere is essential for 
proliferation among cancer cells (Neidle, 2000). Proof-of-concept was achieved as 
quarfloxin, a first in class quadruplex binding small molecule, reached clinical trials 
(Balasubramanian, et al. 2011). 
Anthracenyl isoxazole amides (AIMs), developed in our laboratory, have shown 
potent anti-tumor activity which does not correlate to a traditional mechanism of action 
(Han, et al, 2009). Using computational studies and DNA binding assays we plan to test 
 5 
our hypothesis of AIMs as G4 binders. This hypothesis is backed by preliminary studies 
that suggest AIMs have the potential to interact with G4. In order for these studies to 
advance a more efficient synthesis of intermediates is required 
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Chapter 1: Improved synthesis of 3-aryl isoxazoles containing fused aromatic rings 
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Abstract— A critical comparison of methods to prepare sterically hindered 3-aryl 
isoxazoles containing fused aromatic rings using the nitrile oxide cycloaddition (NOC) 
reveal that modification of the method of Bode, Hachisu, Matsuura and Suzuki (BHMS), 
utilizing either triethyl amine as base or sodium enolates of the diketone, ketoester and 
ketoamide dipolarophiles, respectively was the method of choice for this transformation. 
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Introduction 
Isoxazoles continue to be of interest for both their biological activities and 
synthetic utility.
1-4
 The synthesis of aryl-isoxazoles is also the subject of on-going 
improvements.
1,5-7
 In connection with our studies on aryl isoxazole amides (AIMs)
8-9
 we 
have reported lead compounds which possess (1) useful antitumor activity and  (2) 
photophysical properties which are of potential diagnostic use as "tumor paint".
10
   
An illustration of the application of AIMs is shown in Fig. 1. AIM NSC 728558 
has exhibited a mid-graph mean point of -5.71-5.75 (log scale, which translate to single 
digit micromolar) for tumor cell line growth inhibition (GI50) against the full panel in the 
NCI60 cell line antitumor screening protocol,
8
 and as a benchmark for comparison 
clinically used agents 5-fluorodeoxyuridine, bleomycin and rubidazone gave values of -
4.7, -5.2 and -5.8 respectively in the same standard assay.  The calculated physical 
property data for NSC 728558 fall within or close to values with useful bioavailability 
(radar graph, Symyx Draw v3.1; top right panel). Laser Scanning Cytometry shows that 
NSC 728558 does in fact permeate human glioma SNB-19 cells (the AIM is blue) and is 
localized within the nucleus. Surgical resection of many cancers, especially brain tumors 
or gliomas, have a poor success rate because of the difficulty of judging the border 
between cancerous and healthy tissue. Fluorescent agents with antitumor activity such as 
the AIMs hold promise for improvements in visualizing tumors during surgery.
10b,c
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Fig. 1-1. Structure, Smyx radar graph, and Laser Scanning Cytometry of NSC 728558 
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We required both improvements in the efficiency of the preparation of the 
isoxazole and concomitant economy of scale to prepare amounts of material sufficient to 
expand the scope of our investigations toward in vivo studies.  
Chart 1-1. 1,3-dipolar cycloaddition 
Isoxazoles prepared via nitrile oxide cycloaddition (NOC)
11
 are most often 
prepared by dehydration of a-methylene nitro precursors,
5
 or chlorination/dehalogenation 
of oximes
1,6,7
 to form the nitrile oxide 1.  
Among the unsymmetrical dipolarophiles 2 which usually give rise to 
regioselective cycloaddition are enamines. First pioneered by Stork and McMurry,
12 
the 
use of enamines in the NOC works well for aliphatic and aromatic nitrile oxides on mole 
scales.
1
 We have employed modifications of this synthesis in the preparation of 
isoxazole-oxazolines,
13
 antihypertensive 4-isoxazolyl-1,4-dihydropyridines,
14
 and we  
have championed the reaction as a learning tool for aspiring chemists.
15
 Our previous 
reports in the AIM series have used enamines as dipolarophiles,
16
 while for most cases 
modest yields in the range of 30-40% overall of 3 were obtained, sufficient quantities of 
material were isolated for pharmacology studies. Upon scale-up however, we have 
observed a consistent diseconomy of scale using enamines and nitrile oxides derived 
 10 
from fused ring aromatics, to the extent that even a ten-fold increase in scale  (from ca. 
10 to 100 mM) produced only marginally more desired product, and purified yields 
plummeted to 10-20%. We have found this is especially a limitation when using nitrile 
oxides derived from fused aromatic systems. Careful examination of the reaction by-
products after chromatographic isolation and characterization by LC-MS revealed that as 
the stability of aryl nitrile oxides 1 increases
17,16b
 their consequent reactivity to 
dipolarophiles slows, with concomitant increases in amine trapping  of the nitrile 
oxide/oximidoyl chloride to give 7, as well as self-condensation of the nitrile oxide to 
yield 8 as shown in Scheme 1. 
Scheme 1-1. Synthesis of the isoxazoles used for the present study. 
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We therefore examined the methodology of Bode, Hachisu, Matsuura and Suzuki 
(BHMS), which use either the sodium enolates of ketoesters,
6
 or tertiary amines as base.
7
 
The use of sodium enolates in the NOC was pioneered by Renzi and Dal Piaz,
20
 and 
recently applied in 2,6-disubstituted aryl cases for the preparation of growth hormone 
secretagogue receptor antagonists.
21 
The BHMS procedure has been used to prepare 
particularly hindered unsymmetrical 2,6-disubstituted aryl examples, including examples 
which appear to exist as atropisomers,
7
 which recommended its application to our 
examples. 
Using the BHMS procedure, the yields in all cases where critical comparison was 
made were dramatically improved (Table 1). Symmetrical diketones (Table 1, Entries 1, 
4, 5 and 11-13), unsymmetrical arylalkyl ketones (Table 1, Entries 3, 9 and 10) and 
ketoesters (Table 1, Entries 2, and 6-8) all produced the desired isoxazole products. In 
particularly hindered situations the triethyl amide protocol
7
 often gave higher yields than 
the sodium ethoxide method.
6
 (Table 1, Entries 1, 3, 4 and 7, and compare entry 10 to 9), 
although in a select few cases we have observed that sodium isopropoxide to produce 
slightly higher yield (exemplified by Table 1, Entries 11 and 14). All of the BHMS 
methods gave superior results to our experience using enamines as dipolarophiles for 
fused 3-aryl isoxazoles: for 3b the BHMS conditions gave 70% (Table 1, Entry 2) yield 
compared to 30-40% for the enamine method for which the by-products complicated 
purification and lowered the yield of desired isoxazole (Scheme 1). Similar results were 
observed for 3g the yields were 80% (Table 1, Entry 8) for the BHMS versus 35% for 
enamine (Scheme 1). In cases where the BHMS yields are modest, the enamine 
 12 
methodology gave only traces or no desired product at all that is, the enamine entries (not 
shown) corresponding to Table 1, Entries 3 9,and 10, would correspond to traces at best). 
Table 1-1. Nitrile oxide cycloaddition synthesis of hindered 3-naphthyl-isoxazoles  
Entry 
Nitrile 
Oxide 
Dipolarophile Conditions Product Yield % 
1 1a 
 
Et3N 
3a 
40 
2 1a 
 
Na/EtOH 
3b 
70 
3 1a 
 
Et3N 
3c 
40 
4 1a 
 
Et3N 
3d 
71 
 13 
5 1b 
 
Na/EtOH 
3e 
70 
6 1b 
 
Et3N 
3e 
67 
7 1b 
 
Na/EtOH 
3f 
60 
8 1b 
 
Et3N 
3f 
62 
9 1b 
 
Na/EtOH 
3g 
80 
10 1b 
 
Et3N 
3g 
65 
 14 
11 1b 
 
Na/EtOH 
3h 
15 
12 1b 
 
Et3N 
3h 
22 
13 1b 
 
Na/i-PrOH 
 
3h 
43 
14 1b 
 
Na/EtOH 
3i 
42 
15 1b 
 
Et3N 
3i 
53 
 15 
16 1b 
 
Na/i-PrOH 
 
3i 
57 
 
The comparison was especially dramatic for the anthryl isoxazole cases, shown in 
Table 2. Excellent yields were obtained for anthryl isoxazoles 3j, 10-chloro analog 3k, 
and 10-bromo analog 3m. The yields with the enamine procedures were 35-45
16
 and 10-
20%, for 3j and 3k, respectively. Table 2, Entry 3 illustrates the direct synthesis of a 
fused aromatic containing a C-4 tertiary amide, which is an uncommon example of a 
ketamide used as dipolarophile in the NOC.
22
 The ketamide was prepared from diketene 
and pyrrolidine,
18 
and cycloaddition provided the C-4 amide in synthetically reasonable 
yield. The sluggish reactivity we previously reported for nucleophilic addition to the C-4 
ester of the 3-anthryl-isoxazole is exemplified by (1) slow hydrolysis rates (i.e., 60 h 
using refluxing aqueous LiOH)
9
 and (2) the observation that n-BuLi deprotonates the C-5 
methyl at -78
o
C without noticeable addition to the C-4 ester.
19
 The C-4 functionalization 
prior to the NOC stage is a definite advantage for the preparation of AIMs, and will be 
the subject of further study. 
 
 
 
 
 
 16 
Table 1-2 Nitrile oxide cycloaddition to form hindered 3-anthracenyl-isoxazoles 
Entry 
Nitrile 
Oxide 
Dipolarophile Conditions Product Yield % 
1 1c 
 
Na/EtOH 
3j 
94 
2 1d 
 
Na/EtOH 
3k 
92 
3 1c 
 
Na/EtOH 
3l 
50 
4 1e 
 
Na/EtOH 
3n 
88 
 17 
5 1e 
 
Na/EtOH 
3m 
82 
6 1e 
 
Et3N 
3m 
72 
 
In summary, we have found that the BHMS protocol produced superior results, 
especially in sterically encumbered examples containing fused ring aromatic nitrile 
oxides and that these conditions represent the methodology of choice when standard 
enamine methodology fails. We will report on the chemical and pharmacological 
application of these novel isoxazoles in due course. 
Experimental  
General: 
  All reactions were performed under inert atmosphere. Purification was carried out 
by column chromatography. Chemicals were purchased from TCI or Aldrich Chemical 
Company; all commercial reagents are routinely examined for purity by NMR and TLC, 
and recrystallized or distilled as appropriate. Solvents were reagent grade. Melting points 
were determined in open capillary tubes on a Melt-Temp apparatus and are uncorrected. 
NMR spectra were obtained using either a Varian 400 MHz Unity Plus or a Varian NMR 
systems 500 MHz spectrometer, in deuteriochloroform unless otherwise noted. Infrared 
 18 
spectra were obtained on a thermo-Nicolet 633 FT-IR spectrometer.  
 Chemical shifts (δ) are reported using CHCl3 (7.26 ppm for 
1
H), CDCl3 (77 ppm for 
13
C) as references. High resolution mass spectra (HRMS) were obtained using a 
Micromass electrospray ionization (ESI)/time-of-flight mass spectrometry (LCTOF). 
Mass spectrometer samples were introduced using a Waters model 2690 separations 
module HPLC fitted with a C-18 reversed phase column (2.1 mm i.d., 5 cm). Elemental 
analyses for C, H, and N were performed by Midwest Microlab, Indianapolis, IN. All 
reactions were monitored by Thin Layer Chromatography (TLC). Purification was 
performed by flash column chromatography, and analytical samples were prepared by 
PTLC. Analytical LCMS (UV at 254 nm) and NMR were used to establish the purity of 
targeted compounds. All compounds that were evaluated in biochemical and biophysical 
assays had >95% purity as determined by 
1
H NMR and LCMS NSC 728558 was 
prepared from 3k as previously described.
8,9
 
1-(Pyrrolidin-1-yl)butane-1,3-dione.
18
 Pyrolidine (0.539 g, 7.5 mmol) is dissolved in 10 
mL of anhydrous DCM and diketene (0.925 g, 11.00 mmol) is added. The mixture is 
stirred at ambient temperature for 2.5 h, followed by removal of the solvent under 
vacuum to afford (1.163 g, 99%) as red brown liquid.
 1
H NMR (500 MHz, CDCl3): δ 
3.46 (t, J = 6.62 Hz, 2H), 3.45 (s, 2H), 3.); 
13
C NMR (125 MHz, CDCl3): δ 202.6, 165.0, 
88.8, 51.3, 47.2, 45.9, 30.4, 26.0, 24.4; IR cm
-1
; mass calculated for C8H13NO2 155.0946, 
found m/z 156.1902 (M +1, 100%). 
NOC: sodium enolate method. 
(3-(Anthracen-9-yl)-5-methylisoxazol-4-yl)(pyrrolidin-1-yl)methanone, 3l. To a 
solution of sodium ethoxide, prepared from 0.199 g of Na in 44.2 mL of absolute EtOH, 
 19 
was added 1-(Pyrrolidin-1-yl)butane-1,3-butane-1,3-dione (1.015 g, 6.54 mmol), and 
 
9-
anthrahydroximinoylchloride, (1.06, 4.105 mmol) successively and the resulting red 
solution was stirred under Ar atmosphere for 4h at ambient temperature. The red-brown 
solution was extracted with ethyl acetate (4 x 20 mL), washed with DI water (2 x 50 mL) 
and brine (50 mL), and dried over anhydrous Na2SO4. Filtration and concentration 
afforded the desired product 3l as red-brown oil (1.40 g, 95%), which was further 
purified by silica column flash chromatography (Hexanes: EtOAc; 10:1), and PTLC to 
afford 3l as off white solid (0.7375 g, 50 %). 
NOC: triethyl amine method. Synthesis of 1-(5-methyl-3-(2-methylnaphthalene-1-
yl)isoxazol-4-yl)ethanone, 3a. To 2,4-pentanedione (0.42 g, 4.11 mmol)  in absolute 
ethanol (21ml) at ambient temperature was added triethylamine (0.47 g, 4.584 mmol) 
followed by addition of nitrile oxide (0.6 g, 3.28 mmol). The temperature was raised to 
53
o
C and the mixture stirred under Ar atmosphere for 72 h. The pale yellow solution was 
extracted with chloroform (4 x 20 mL), washed with DI water (2 x 50 mL) and brine (50 
mL), dried over anhydrous Na2SO4. Filtration, concentration and silica column flash 
chromatography (Hexanes: EtOAc: DCM; 5:1:1) afforded the desired product 3a (0.289 
g, 40 %): 
Analytical data for 3-fused aryl isoxazole products. 
1-(5-Methyl-3-(2-methylnaphthalene-1-yl)isoxazol-4-yl)ethanone, 3a. Oil, TLC SiO2 
hexane-DCM-EtOAc 4:1:1 Rf 0.77. 
1
H NMR (500 MHz, CDCl3) δ 7.80-7.75 (m, 2H), 
7.38-7.32 (m, 4H), 2.76 (s, 3H), 2.26 (s, 3H), 1.56 (s, 3H); 
13
C NMR (125 MHz, CDCl3) 
δ 192.3, 175.7, 159.6, 135.3, 132.3, 131.4, 129.5, 127.8, 126.8, 125.2, 124.0, 117.5, 28.6, 
19.8, 13.6; HRMS Calc'd for C17H16NO2 266.1181; Found: 266.1193. 
 20 
Ethyl 3-(2-methylnaphthalen-1-yl)-5-methylisoxazole-4-carboxylate, 3b. Oil, TLC 
SiO2 hexane-DCM-EtOAc 4:1:1 Rf
 
0.6. 
1
H-NMR (CDCl3) d 7.826 (d, 2H); 7.25-7.398(m, 
4H); 3.87 (q, 2H); 2.841 (s, 3H); 2.303 (s, 3H); 0.651 (t, 3H). 
13
C NMR (125 MHz, 
CDCl3) δ 175.7, 161.4, 160.7, 135.0, 132.5, 131.4, 128.9, 127.9, 127.7, 126.2, 124.8, 
124.6, 124.5, 110.1, 59.9, 20.1, 13.2, 13.0. HRMS calc'd for C18H18NO3: 296.1287; 
Found: 296.1297.  
Phenyl (5-methyl-3-(2-methylnaphthalen-1-yl)isoxazol-4-yl)methanone, 3c. Oil, TLC 
SiO2 hexane-DCM-EtOAc 4:1:1 Rf 0.79 
1
H NMR (500 MHz, CDCl3): δ 7.65 (d, J = 7.90, 
1H), 7.60 (d, J = 8.50 Hz, 1H), 7.55 (d, J = 8.00 Hz, 1H), 7.37 (t, J = 6.60 Hz, 1H), 7.33 
(m, 3H), 7.16 (m, 2H), 6.94 (t, J = 8.00 Hz, 2H), 3.38 (s, 3H), 2.64 (s, 3H); 
13
C NMR 
(125 MHz, CDCl3): δ  189.8, 173.7, 171.0, 160.3, 137.1, 135.5, 132.4, 132.3, 131.4, 
129.3, 129.2, 128.1, 128.0, 127.9, 127.8, 127.5, 125.0, 124.5, 124.4, 123.6, 117.8, 20.4, 
14.0; HRMS Calc'd for C22H18NO2: 328.1338; Found: 328.1370.  
6,6-Dimethyl-3-(2-methylnaphthalen-1-yl)-6,7-dihydrobenzo[d]isoxazol-4(5H)-one 
3d. Oil, TLC SiO2 hexane-DCM-EtOAc 4:1:1 Rf 0.71. 
1
H NMR (500 MHz, CDCl3) δ 
7.87 (d, J = 8.3, 1H), 7.84 (d, J = 8.3, 1H), 7.36-7.43 (m, 4H), 3.01 (s, 2H), 2.40 (d, J = 
8.3, 2H), 2.31 (s, 3H), 1.22 (s, 3H), 1.19 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 190.8, 
180.9, 171.1, 157.9, 135.6, 132.3, 131.7, 129.7, 129.6, 128.4, 128.2, 128.1, 128.0, 125.2, 
125.0, 124.5, 124.3, 122.9, 52.4, 37.0, 35.5, 28.6, 28.5, 28.1, 28.0, 21.0, 14.2. HRMS 
Calc'd for C20H20NO2: 306.1494; Found: 306.1516.   
1-(3-(2-methoxynaphthalene-1-yl)-5-methylisoxazol-4-yl)ethanone, 3e. Oil, TLC SiO2 
hexane-DCM-EtOAc 4:1:1 Rf 0.53.  
1
H NMR (500 MHz, CDCl3) δ 8.01 (d, J = 9.30 Hz, 
1H), 7.84 (d, J = 7.80 Hz, 1H), 7.48 (d, J = 8.30 Hz, 1H), 7.44 (t, J = 8.30 Hz, 1H), 7.39 
 21 
(d, J = 7.90 Hz, 1H), 7.36 (d, J = 8.80 Hz, 1H), 3.90 (s, 3H), 2.81 (s, 3H), 1.76 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 193.2, 175.4, 157.7, 155.3, 133.3, 132.1, 128.7, 128.1, 
127.8, 124.2, 123.9, 118.3, 112.6, 111.4, 56.4, 28.8, 14.0. HRMS Calc'd for M+H, 
C17H16NO3 282.1130; Found: 282.1150 (M +1, 100%). Anal Calc'd for C17H15NO3: C, 
72.58; H, 5.37; N, 4.98. Found: C, 71.81; H, 5.52; N, 4.56. 
Methyl 3-(2-methoxynaphthalene-1-yl)-5-methylisoxazole-4-carboxylate, 3f. Oil, 
TLC SiO2 hexane-DCM-EtOAc 4:1:1 Rf 0.56. 
1
H NMR (500 MHz, CDCl3): δ 7.96 (d, J 
= 9.05 Hz, 1H), 7.82 (d, J = 9.99 Hz, 1H), 7.55 (d, J = 9.99 Hz, 1H), 7.40 (t, J = 9.99 Hz, 
1H), 7.35 (t, J = 9.99 Hz, 2H), 3.86 (s, 3H), 3.54 (s, 3H), 2.81 (s, 3H); 
13
C NMR (500 
MHz, CDCl3): δ 175.1, 162.1, 158.5, 155.3, 133.0, 131.3, 128.6, 127.9, 127.0, 124.0, 
123.6, 112.6, 111.4, 110.4, 56.4, 51.3, 13.3; IR cm
-1
; HRMS Calc'd for C17H16NO4: 
298.1079; Found 298.1111. Anal. Calc'd for C17H15NO4: C, 68.68; H, 5.09; N, 4.71. 
Found: C, 66.81; H, 5.00; N, 4.53. 
Ethyl 3-(2-methoxynaphthalen-1-yl)-5-methylisoxazole-4-carboxylate, 3g, as yellow 
solid (1.8 g, 60 %): mp 103-104
o
C; 
1
H NMR (500 MHz, CDCl3): δ 7.96 (d, J = 8.99 Hz, 
1H), 7.81 (d, J = 8.07 Hz, 1H), 7.50 (d, J = 8.55 Hz, 1H), 7.39 (dd, J = 11.00, 6.84 Hz 
1H), 7.34 (d, J = 9.05 Hz, 2H), 3.96 (q, J = 7.06 Hz, 2H), 3.88 (s, 3H), 2.82 (s, 3H), 0.79 
(t, J = 7.06 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 175.3, 161.9, 158.6, 155.3, 133.3, 
131.3, 128.6, 127.9, 127.1, 124.1, 123.7, 112.7, 111.8, 110.6, 60.1, 56.5, 13.5, 13.3; ESI-
MS Calculated for C18H17NO4+H m/z 312.1428 (M +1, 100 %). Anal Calc'd for 
C18H17NO4: C, 69.44; H, 5.50; N, 4.50. Found: C, 69.58; H, 5.47; N, 4.54. 
Phenyl (3-(2-methoxynaphthalen-1-yl)-5-methylisoxazol-4-yl) methanone, 3h. mp 
141-142 
o
C; 
1
H NMR (500 MHz, CDCl3): δ 8.06 (d, J = 8.50, 1H), 7.73 (d, J = 8.80 Hz, 
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2H), 7.51 (t, J = 8.40 Hz, 1H), 7.44 (d, J = 8.30 Hz, 2H), 7.36 (t, J = 7.55 Hz, 1H), 6.96 
(t, J = 7.80 Hz, 2H), 6.90 (d, J = 9.30  Hz, 1H), 3.61 (s, 3H), 2.69 (s, 3H); 
13
C NMR (125 
MHz, CDCl3): δ  189.8, 173.2, 157.8, 154.5, 137.1, 132.7, 132.4, 131.7, 128.7, 128.5, 
128.0, 127.7, 127.5, 124.2, 117.6, 111.6, 78.1 55.5, 29.7; ESI-MS for C22H17NO3+Hm/z 
344.1008 (M +1, 100%).  
6,6-dimethyl-3-(2-methoxynaphthalen-1-yl)--6,7-dihydrobenzo[d]isoxazol-4(5H)-
one, 3i. Oil, TLC SiO2 hexane-DCM-EtOAc 4:1:1 Rf 0.46. 
1
H NMR (500 MHz, CDCl3) 
δ 7.96 (d, J = 9.1, 1H), δ 7.81 (d, J = 7.8 Hz, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.43 (dt, J = 
9.8 Hz, 1.5 Hz, 1H), 7.36 (dd, J = 6.8 Hz, 1.3 Hz, 1H), 7.34 (d, J = 9.3 Hz, 2H), 3.85 (s, 
3H), 2.90 (s, 2H), 2.36 (q, J = 14.7 Hz, 2H), 1.17 (s, 3H), 1.14 (s, 3H); 
13
C NMR (125 
MHz, CDCl3) δ 190.7, 180.2, 155.7, 155.4, 132.6, 131.7, 131.6, 128.6, 128.1, 128.0, 
127.9, 127.8, 127.6, 127.2, 126.9, 123.9, 123.7, 123.4, 115.2, 112.9, 112.8, 112.6, 109.9, 
56.4, 56.2, 52.3, 36.7, 35.1, 28.3, 28.0. HRMS Calculated for C20H20NO3 322.1443; 
Found: 322.1458. 
Ethyl 3-(anthracen-9-yl)-5-methylisoxazole-4-carboxylate, 3j. mp 121-122
o
C; TLC 
SiO2 hexane-EtOAc 10:1, Rf 0.30. 
1
H NMR (500 MHz, CDCl3): δ 8.58 (s, 1H), 8.05 (d, J 
= 8.31 Hz, 2H), 7.65 (d, J = 8.55 Hz, 2H), 7.40-7.49 (m, 4H), 3.71 (q, J = 7.21 Hz, 2H), 
2.93 (s, 3H), 0.32 (t, J = 7.10 Hz, 3H); 
13
C NMR (500 MHz, CDCl3): 176.2, 161.5, 160.5, 
131.0, 130.8, 128.7, 128.5, 126.3, 125.4, 125.2, 122.7, 111.4, 60.1, 13.5, 12.8, spectral 
data are in accord with those reported previously.
16a
 ESI-MS for C21H17NO3+H m/z 
332.1441 (M +1, 100%). 
Ethyl 3-(10-chloroanthracen-9-yl)-5-methylisoxazole-4-carboxylate, 3k. mp 123-
124
o
C, lit. mp 119-120.
16b 
TLC SiO2 hexane-EtOAc 10:1, Rf 0.28. 
1
H NMR (500 MHz, 
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CDCl3): δ 8.59 (d, J = 8.80 Hz, 2H), 7.53 - 7.60 (m, 4H), 7.43 (d, J = 8.80 Hz, 2H), 3.72 
(q, J = 7.1 Hz, 2H), 2.93 (s, 3H), 0.39 (t, J = 7.1 Hz, 3H); 
13
C NMR (500 MHz, CDCl3): 
177.3, 161.3, 161.2, 134.1, 131.1, 128.3, 126.7, 125.9, 125.1, 122.6, 111.5, 60.2, 13.2; 
ESI-MS for C21H16ClNO3+H m/Z 366.0886 (M +1, 95%). 
[3-(Anthracen-9-yl)-5-methylisoxazol-4-yl](pyrrolidin-1-yl)methanone, 3l. mp  194-
5
o
C. 
1
H NMR (500 MHz, CDCl3): δ 8.54 (s, 1H), 7.99 (d, J = 9.29 Hz, 2H), 7.95 (d, J = 
10.0 Hz, 2H), 7.48-7.45 (m, 4H), 3.10 (t, J = 6.87 Hz, 2H), 2.73 (s, 3H), 2.60 (t, J = 6.61 
Hz, 2H),  1.42 (pentet, J = 6.85 Hz, 2H), 1.29 (pentet, J = 6.60 Hz, 2H);
 13
C NMR (125 
MHz, CDCl3): δ 170.1, 161.3, 158.3, 131.0, 130.5, 129.4, 128.5, 126.9, 126.7, 125.8, 
125.3, 125.0, 121.9, 116.5, 47.7, 45.3, 25.6, 23.7, 12.4; ESI-MS for C23H20N2O2+H, m/z 
357.0757 [M +1, (100)]. Anal Calc'd for C23H20N2O2: C, 77.51; H, 5.66; N, 7.86. Found: 
C, 77.37; H, 5.45; N, 7.99.   
Methyl 3-(10-bromoanthracen-9-yl)-5-methylisoxazole-4-carboxylate, 3m. Rf=0.45 
Hex:EtOAc:DCM 4:1:1
1
H NMR (500 MHz, CDCl3): 8.63-8.60 (d,2H), 7.62-7.59 
(m,4H), 7.47-7.43 (m,2H), 3.32 (s,3H), 2.93 (s,3H). 
13
C NMR (125 MHz, CDCl3): 
176.08, 163.32, 161.53, 131.12, 129.90, 127.96, 126.88, 126.39, 125.60, 123.12, 51.35, 
13.42. HRMS Calc'd for M+H C20H14NO3
79
Br+H, m/z 396.0227; Found: 396.0235. 
Laser Scanning Cytometry Methods: SNB-19 human glioblastoma cells (American 
Type Cell Culture Cat No. CRL-2266) were plated at a density of 2000 cells/mL on cover 
slips in RPMI medium (with L-glutamine and penicillin/streptomycin and supplemented 
with 10% fetal bovine serum).  Cell culture medium and supplements were obtained from 
VWR (West Chester, PA).  The cells were incubated at 37 C under a humidified 
atmosphere containing 5% CO2 and allowed to adhere. Medium was aspirated and 
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replaced with 1 µM NSC 728558 for 24-h exposure. Drug was removed and cells were 
washed twice with phosphate buffered saline (PBS). Cells were fixed in 4% 
paraformaldehye (15 min, 21 C) and washed once with PBS. Following two additional 
washes, slides were inverted to microscope slides and sealed using FluorSave Reagent 
(Calbiochem). Images were generated from scans from a CompuCyte iCys Laser 
Scanning Cytometer.  (CompuCyte, Westwood, MA).  Cells were scanned with a 405 nm 
30 mW Diode laser.  Fluorescent signals were measured in photo-multiplier detectors 
following a 440/30 Band-pass (BP) filter to detect NSC 728558 presence.  Light 
absorption was also measured to produce a differential interference contrast (DIC)-like 
image for cell morphology.  Each signal was given a pseudo-color and overlaid to 
produce images.   
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Supplementary Material 
Representative HPLC trace for  3m. Characterization data for by-products 7 and 8, 
representative spectra for products 3. 
7b. Rf 0.11. ESI- MS Calculated for C16H18N2O2 FW 270, observed m/z 271 [M 
+1
+
100% Rel. I.]. 
8b. Rf 0.05. ESI- MS Calculated for C24H18N2O2 FW 366, observed m/z 367 [M +1
+ 
80% 
Rel. I.]; 733 (100). 
8g. mp 177-178 
o
C; 
1
H NMR (500 MHz, CDCl3): δ 8.09 (t, J = 8.68 Hz, 1H), 8.03 (d, J = 
9.05 Hz, 2H), 7.87 (t, J = 8.32 Hz, 3H), 7.56-7.49 (m, 2H), 7.44-7.39 (m, 4H), 4.06 (s, 
3H), 4.02 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 174.0, 165.7, 157.5, 156.5, 134.0, 
133.3, 132.7, 132.4, 128.7, 128.6, 128.3, 128.2, 128.1, 127.6, 124.4, 124.3, 124.2, 124.0, 
113.2, 112.9, 110.3, 107.7, 57.0, 56.8.  
7k. ESI- MS Calculated for C19H17
35
ClN2O2 FW 340.10, observed m/z 341.6145 
[C19H17
35
ClN2O2, M +1
+
 100% Rel. I.], 343.6289 [C19H17
37
ClN2O2, 37]. 
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Fig. 1-2. HPLC trace for 3m 
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Fig. 1-3. Proton spectrum for 3m
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Fig. 1-4. Carbon spectrum for 3m 
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Fig. 1-5. Proton spectrum for 7k 
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Chapter 2: Crystal Structure of Ethyl 3-(10'-bromo-9'-anthracenyl)-5-methyl-4-
isoxazolcarboxylate 
This manuscript will be submitted for publication to Acta Crystrallographica 
The title compound adopts a conformation in which the isoxazole and anthryl 
mean planes are slightly deviated from the orthogonal. The aromatic anthracene ring is 
fairly planar, and the isoxazole is almost completely planar. The dihedral angle between 
the carbonyl and isoxazole of is indicative of resonance, also reflected in the bond-length. 
The isoxazole ethyl ester resides over the shielding cone of the anthryl, which is 
maintained in solution as evidenced by magnetic anisotropy of the average conformation 
at room temperature. 
Fig. 2-1. Crystal structure of title compound 
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studies on anthryl isoxazole crystallography, see: Mosher (1996); Han, (2002); Han, 
(2003); Li, (2006); Li (2008). For the antitumor activity of aryl isoxazole amides (AIMs), 
see:  Han, et al. (2009); Gajewski, et al (2009). 
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Supplementary Materials 
Comment 
The aryl isoxazole amides (AIMs)
1,2
 have significant activity  in the National Cancer 
Institute’s 60 cell line screen, 
3,4 
comparable to several agents in general medical practice, 
such as fluorouridine and bleomycin.
5
 Our working hypothesis for developing the 
structure activity relationship (SAR) of AIMs to improve their anti-tumor efficacy is 
focused on the quadruplex DNA conformations.
6,7
 To more accurately inform our G-4 - 
small molecule docking studies, we rely on crystallographic determinations of AIMs. In 
previous studies we have determined that the dihedral angle between the isoxazole and 
the C-3 aryl is approximately orthogonal, and we have postulated that this is a critical 
feature in the biological activity of the AIMs. For example, the anthracenyl group is 
almost perpendicular to the isoxazole plane, in Ethyl 3-(10-chloroanthracenyl)-5-(1-
phenyl-2-hydroxylethylenyl)isoxazole-4-carboxylate 85.51(4),
8
 which is similar to 
analogous anthracenyl isoxazole structures in the Cambridge Structural Database, i.e. 
ethyl 3-(10'-chloro-9'-anthracenyl)-5-methyl-4-isoxazolcarboxylate, 74.3  (Han et al., 
2003; CSD refcode EZENEC),
10
 ethyl 3-(10'-chloro-9'-anthracenyl)-5-(2-phenylethyl)-4-
isoxazolecarboxylate, 78.5 (Han et al., 2002; CSD refcode MUQMOA),
11 
 This AIM 
analog represents a key intermediate in future synthesis and SAR studies, and our 
progress will be reported in due course. 
Experimental Section 
To a suspension of anthracene-9-carbaldehyde (2.0 g, 9.7 mmol) in dichloromethane (70 
mL) was added a solution of bromine (1.86 g, 11.64 mmol) in dichloromethane (6 mL) at 
room temperature. The solution was then brought to reflux and allowed to stir for 4 
 36 
hours. The temperature was decreased to -5 °C and stirring continued for another 30 
minutes. The precipitate was filtered and washed with cold hexanes to afford 2.2 g (80 
%) of a brown solid. The precipitate was purified via crystallization from CHCl3 to yield 
1.9 g (70%) pure 10-bromoanthracene-9-carbaldehyde. 
1
H NMR (CDCl3) δ 11.51 (s, 1H), 
8.90 (m, 2H), 8.68 (m, 2H), 7.69 (m, 4H). 
To a solution of 10-bromoanthracene-9-carbaldehyde in THF: EtOH: H2O (12 mL: 6 
mL: 6 mL) was dissolved sodium acetate (1.9 g, 15.78 mmol) and hydroxylamine 
hydrochloride (0.8 g, 10.53 mmol). The reaction was allowed to stir at room temperature 
for 4 days. After 24 hours a large amount of bright yellow precipitate had formed. The 
mixture was placed under reduced pressure to remove THF and EtOH. The resulting 
material was diluted with ethyl acetate (50 mL), washed with brine (4 x 50 mL), and 
water (2 x 50 mL). The combined aqueous fractions were then extracted with chloroform 
(3 x 50 mL). The combined organic solutions were dried over sodium sulfate, filtered, 
and concentrated in vacuo to yield 1.56 g of 10-bromoanthracene-9-carbaldehyde oxime  
(>99%).
1
H NMR(CDCl3) δ 9.22 (s, 1H), 8.51 (s, 1H), 8.42 (d, J=8.66 Hz, 2H), 8.03 (d, 
J=8.16 Hz, 2H), 7.55 (m, 4H);  
To a round bottom flask containing 10-bromoanthracene-9-carbaldehyde oxime (1.05 g, 
3.50 mmol) was added chloroform (20 mL) and pyridine (0.350 mmol). To the resulting 
mixture was added N-bromosuccinimide (0.685 g, 3.85 mmol) portion-wise over 5 
minutes. The flask was equipped with a water condenser and the temperature was raised 
to 40 °C. The resulting turbid mixture was allowed to stir under a balloon of argon for 4 
hours. The orange solution with white precipitate was cooled to room temperature and 
diluted with dichloromethane (150 mL). The resulting solution was washed with brine (3 
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x 100 mL) and water (2 x 100 mL) before being dried over sodium sulfate. The solution 
was filtered and concentrated under reduced pressure to yield 1.3 g of the 10-bromo-N-
hydroxyanthracene-9-carbimidoyl bromide which can be carried on to the next reaction 
without further purification.  
Under argon, was added ethylacetoacetate (3.10 g, 26.68 mmol) to a solution of sodium 
ethoxide, prepared by dissolving sodium (0.584 g, 25.4 mmol) in ethanol (100 mL). The 
resulting solution was then added to a round bottom flask containing 10-bromo-
anthracenyl-nitrile oxide (3.8 g, 12.70 mmol). The reaction was allowed to stir at room 
temperature under argon for 6 hours. The volatiles were removed in vacuo and the 
resulting brown oil was dissolved in ethyl acetate, washed with brine (4 x 50 mL), and 
water (4 x 50 mL). The organic layer was then dried over sodium sulfate, filtered, and 
concentrated to yield 5.2 g of brown solid. The solid was then purified via column 
chromatography eluting 4:1:1 hexanes: ethylacetate: dichloromethane to yield 4.6 g of 
orange oil (88 %) which was re-crystallized from CHCl3 and hexanes to yield pure ethyl 
3-(anthracen-9-yl)-5-methylisoxazole-4-carboxylate.
 1
H NMR (CDCl3) δ 8.61 (d, J=8.9 
Hz, 2H), 7.61 (m, 4H), 7.46 (m, 2H), 3.71 (q, J=7.1 x (3) Hz, 2H), 2.93 (s, 3H), 0.38 (t, 
J=7.2 x (2) Hz, 3H) 
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Fig. 2-2. 3-aryl isoxazole carboxylates 
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Fig. 2-3. Side view of the title compound 
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Crystal data 
C21H18BrNO3  ? 
Mr = 412.27 Dx = 1.578 Mg m
−3
 
Monoclinic, P21/c Melting point: ? K 
Hall symbol: ? ? radiation, λ = 0.71073 Å 
a = 8.8554 (4) Å Cell parameters from 9851 reflections 
b = 16.7298 (8) Å θ = 2.4–28.9° 
c = 11.7218 (6) Å µ = 2.39 mm
−1
 
β = 92.456 (1)° T = 100 K 
V = 1734.98 (14) Å
3
 Prism 
Z = 4 × × mm 
F(000) = 840 
 
 
Data collection 
?  
diffractometer 
4331 independent reflections 
Radiation source: ? 3979 reflections with I > 2σ(I) 
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? Rint = 0.020 
Detector resolution: 8.3333 pixels mm
-
1
 
θmax = 29.0°, θmin = 2.1° 
? h = −11 11 
Absorption correction: multi-scan  
SADABS V2012/1 (Bruker AXS Inc.) 
k = −22 22 
Tmin = ?, Tmax = ? l = −15 15 
20906 measured reflections 
 
Refinement 
Refinement on F
2
 
Secondary atom site location: difference 
Fourier map 
Least-squares matrix: full 
Hydrogen site location: inferred from 
neighbouring sites 
R[F
2
 > 2σ(F
2
)] = 0.028 
H atoms treated by a mixture of 
independent and constrained refinement  
wR(F
2
) = 0.077 
w = 1/[σ
2
(Fo
2
) + (0.043P)
2
 + 1.6812P]  
where P = (Fo
2
 + 2Fc
2
)/3 
S = 1.01 (Δ/σ)max = 1.401 
4331 reflections Δρmax = 0.56 e Å
−3
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237 parameters Δρmin = −0.35 e Å
−3
 
0 restraints Extinction correction: none 
? constraints Extinction coefficient: ? 
Primary atom site location: structure-
invariant direct methods  
 
Refinement of F
2
 against ALL reflections. The weighted R-factor wR and goodness of fit 
S are based on F
2
, conventional R-factors R are based on F, with F set to zero for 
negative F
2
. The threshold expression of F
2
 > 2sigma(F
2
) is used only for calculating R-
factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors 
based on F
2
 are statistically about twice as large as those based on F, and R- factors based 
on ALL data will be even larger. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å
2
)  
 
x y z Uiso*/Ueq 
 
Br1 0.658986 (19) 0.809934 (10) 0.627818 (16) 0.02147 (7) 
 
N1 0.15852 (15) 0.53042 (8) 0.85626 (12) 0.0138 (3) 
 
O1 0.06573 (13) 0.46169 (7) 0.84085 (10) 0.0141 (2) 
 
O2 0.14984 (16) 0.42450 (8) 0.49115 (11) 0.0257 (3) 
 
O3 0.29600 (13) 0.53325 (7) 0.52104 (9) 0.0140 (2) 
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C1 0.72847 (18) 0.66328 (10) 0.79021 (15) 0.0167 (3) 
 
H1 0.7992 0.703 0.77 0.02* 
 
C2 0.77600 (19) 0.60075 (11) 0.85719 (15) 0.0182 (3) 
 
H2 0.8788 0.5977 0.8834 0.022* 
 
C3 0.67314 (19) 0.54026 (10) 0.88806 (14) 0.0163 (3) 
 
H3 0.7076 0.4969 0.9345 0.02* 
 
C4 0.52499 (18) 0.54413 (10) 0.85133 (13) 0.0136 (3) 
 
H4 0.4575 0.5031 0.8725 0.016* 
 
C5 0.11132 (19) 0.68191 (9) 0.63023 (13) 0.0131 (3) 
 
H5 0.0415 0.6422 0.652 0.016* 
 
C6 0.06338 (19) 0.74251 (10) 0.55974 (14) 0.0164 (3) 
 
H6 −0.0392 0.7444 0.5325 0.02* 
 
C7 0.1655 (2) 0.80264 (10) 0.52684 (15) 0.0180 (3) 
 
H7 0.1308 0.8445 0.4776 0.022* 
 
C8 0.3129 (2) 0.80097 (10) 0.56505 (14) 0.0160 (3) 
 
H8 0.3796 0.8419 0.5423 0.019* 
 
C9 0.52036 (18) 0.73206 (9) 0.67841 (13) 0.0130 (3) 
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C10 0.31828 (17) 0.61286 (9) 0.73969 (12) 0.0104 (3) 
 
C11 0.46917 (17) 0.60896 (9) 0.78133 (12) 0.0108 (3) 
 
C12 0.57439 (18) 0.67033 (9) 0.74985 (13) 0.0127 (3) 
 
C13 0.36903 (18) 0.73849 (9) 0.63891 (13) 0.0123 (3) 
 
C14 0.26538 (18) 0.67730 (9) 0.67179 (13) 0.0111 (3) 
 
C15 0.21509 (17) 0.54416 (9) 0.75653 (13) 0.0107 (3) 
 
C16 0.16290 (17) 0.48643 (9) 0.67370 (13) 0.0112 (3) 
 
C17 0.07011 (17) 0.43727 (9) 0.73183 (13) 0.0124 (3) 
 
C18 −0.0206 (2) 0.36570 (10) 0.69868 (15) 0.0179 (3) 
 
H9 −0.1069 0.3613 0.7479 0.027* 
 
H10 0.0425 0.3178 0.7073 0.027* 
 
H11 −0.0573 0.3708 0.6189 0.027* 
 
C19 0.19959 (18) 0.47697 (10) 0.55273 (13) 0.0132 (3) 
 
C20 0.34582 (19) 0.52867 (10) 0.40446 (14) 0.0160 (3) 
 
H12 0.258 0.5222 0.3501 0.019* 
 
H13 0.4147 0.4827 0.3959 0.019* 
 
C21 0.4270 (2) 0.60611 (11) 0.38219 (15) 0.0205 (3) 
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H15 0.5123 0.6122 0.4376 0.031* 
 
H14 0.357 0.651 0.3898 0.031* 
 
H16 0.4644 0.6055 0.3047 0.031* 
 
 
Atomic displacement parameters (Å
2
)  
 
U
11
 U
22
 U
33
 U
12
 U
13
 U
23
 
Br1 
0.01677 
(10) 
0.01705 
(10) 
0.03110 
(11) 
−0.00376 
(6) 
0.00684 
(7) 
0.00298 
(6) 
N1 0.0149 (6) 0.0123 (6) 0.0142 (6) −0.0032 (5) 0.0016 (5) 
−0.0003 
(5) 
O1 0.0150 (5) 0.0135 (5) 0.0138 (5) −0.0032 (4) 0.0025 (4) 0.0012 (4) 
O2 0.0331 (7) 0.0276 (7) 0.0166 (6) −0.0155 (6) 0.0051 (5) 
−0.0083 
(5) 
O3 0.0171 (6) 0.0145 (5) 0.0107 (5) −0.0029 (4) 0.0043 (4) 
−0.0021 
(4) 
C1 0.0117 (7) 0.0170 (8) 0.0214 (8) −0.0015 (6) 0.0008 (6) 
−0.0032 
(6) 
C2 0.0120 (7) 0.0222 (8) 0.0202 (8) 0.0013 (6) 
−0.0028 
(6) 
−0.0048 
(7) 
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C3 0.0171 (8) 0.0179 (8) 0.0136 (7) 0.0038 (6) 
−0.0021 
(6) 
−0.0007 
(6) 
C4 0.0153 (7) 0.0139 (7) 0.0114 (7) −0.0002 (6) 0.0001 (5) 
−0.0002 
(5) 
C5 0.0141 (7) 0.0122 (7) 0.0129 (7) 0.0000 (5) 0.0006 (6) 
−0.0025 
(5) 
C6 0.0160 (7) 0.0174 (8) 0.0155 (7) 0.0035 (6) 
−0.0018 
(6) 
−0.0026 
(6) 
C7 0.0229 (9) 0.0154 (8) 0.0155 (8) 0.0048 (6) 0.0007 (6) 0.0027 (6) 
C8 0.0204 (8) 0.0124 (7) 0.0154 (7) 0.0002 (6) 0.0040 (6) 0.0015 (6) 
C9 0.0131 (7) 0.0104 (7) 0.0158 (7) −0.0031 (5) 0.0054 (6) 
−0.0014 
(6) 
C10 0.0116 (7) 0.0105 (7) 0.0092 (6) −0.0005 (5) 0.0015 (5) 
−0.0019 
(5) 
C11 0.0117 (7) 0.0110 (7) 0.0098 (6) 0.0004 (5) 0.0012 (5) 
−0.0022 
(5) 
C12 0.0120 (7) 0.0129 (7) 0.0135 (7) −0.0005 (5) 0.0018 (5) 
−0.0036 
(6) 
C13 0.0152 (7) 0.0107 (7) 0.0112 (6) −0.0001 (5) 0.0026 (5) −0.0017 
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(5) 
C14 0.0128 (7) 0.0108 (7) 0.0098 (6) 0.0003 (5) 0.0014 (5) 
−0.0022 
(5) 
C15 0.0105 (7) 0.0100 (7) 0.0116 (7) 0.0017 (5) 0.0000 (5) 0.0009 (5) 
C16 0.0104 (6) 0.0113 (7) 0.0118 (7) −0.0003 (5) 
−0.0007 
(5) 
−0.0003 
(5) 
C17 0.0113 (7) 0.0121 (7) 0.0138 (7) 0.0016 (5) 
−0.0006 
(5) 
0.0012 (5) 
C18 0.0177 (8) 0.0131 (7) 0.0226 (8) −0.0043 (6) 
−0.0016 
(6) 
0.0017 (6) 
C19 0.0129 (7) 0.0141 (7) 0.0126 (7) −0.0001 (6) 0.0004 (5) 
−0.0007 
(6) 
C20 0.0202 (8) 0.0177 (8) 0.0105 (7) 0.0009 (6) 0.0048 (6) 
−0.0006 
(6) 
C21 0.0234 (9) 0.0214 (8) 0.0173 (8) −0.0023 (7) 0.0063 (6) 0.0026 (6) 
 
Geometric parameters (Å, °) 
Br1—C9 1.9022 (15) C8—C13 1.433 (2) 
N1—C15 1.312 (2) C8—H8 0.95 
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N1—O1 1.4203 (17) C9—C12 1.401 (2) 
O1—C17 1.3438 (19) C9—C13 1.403 (2) 
O2—C19 1.208 (2) C10—C11 1.404 (2) 
O3—C19 1.3344 (19) C10—C14 1.408 (2) 
O3—C20 1.4558 (18) C10—C15 1.487 (2) 
C1—C2 1.364 (2) C11—C12 1.445 (2) 
C1—C12 1.430 (2) C13—C14 1.439 (2) 
C1—H1 0.95 C15—C16 1.432 (2) 
C2—C3 1.419 (2) C16—C17 1.365 (2) 
C2—H2 0.95 C16—C19 1.477 (2) 
C3—C4 1.365 (2) C17—C18 1.484 (2) 
C3—H3 0.95 C18—H9 0.98 
C4—C11 1.435 (2) C18—H10 0.98 
C4—H4 0.95 C18—H11 0.98 
C5—C6 1.364 (2) C20—C21 1.510 (2) 
C5—C14 1.431 (2) C20—H12 0.99 
C5—H5 0.95 C20—H13 0.99 
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C6—C7 1.417 (2) C21—H15 0.98 
C6—H6 0.95 C21—H14 0.98 
C7—C8 1.362 (3) C21—H16 0.98 
C7—H7 0.95 
  
C15—N1—O1 105.64 (12) C1—C12—C11 118.26 (15) 
C17—O1—N1 109.08 (12) C9—C13—C8 123.85 (14) 
C19—O3—C20 116.58 (12) C9—C13—C14 117.93 (14) 
C2—C1—C12 121.36 (16) C8—C13—C14 118.19 (15) 
C2—C1—H1 119.3 C10—C14—C5 121.52 (14) 
C12—C1—H1 119.3 C10—C14—C13 119.71 (14) 
C1—C2—C3 120.55 (15) C5—C14—C13 118.71 (14) 
C1—C2—H2 119.7 N1—C15—C16 111.20 (14) 
C3—C2—H2 119.7 N1—C15—C10 120.94 (13) 
C4—C3—C2 120.31 (15) C16—C15—C10 127.86 (14) 
C4—C3—H3 119.8 C17—C16—C15 104.56 (13) 
C2—C3—H3 119.9 C17—C16—C19 125.22 (14) 
C3—C4—C11 121.28 (15) C15—C16—C19 130.20 (14) 
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C3—C4—H4 119.4 O1—C17—C16 109.51 (13) 
C11—C4—H4 119.4 O1—C17—C18 117.19 (14) 
C6—C5—C14 120.91 (15) C16—C17—C18 133.30 (15) 
C6—C5—H5 119.5 C17—C18—H9 109.5 
C14—C5—H5 119.6 C17—C18—H10 109.5 
C5—C6—C7 120.45 (15) H9—C18—H10 109.5 
C5—C6—H6 119.8 C17—C18—H11 109.5 
C7—C6—H6 119.8 H9—C18—H11 109.5 
C8—C7—C6 120.65 (15) H10—C18—H11 109.5 
C8—C7—H7 119.7 O2—C19—O3 124.60 (15) 
C6—C7—H7 119.7 O2—C19—C16 124.20 (15) 
C7—C8—C13 121.09 (15) O3—C19—C16 111.19 (13) 
C7—C8—H8 119.4 O3—C20—C21 106.43 (13) 
C13—C8—H8 119.5 O3—C20—H12 110.4 
C12—C9—C13 123.42 (14) C21—C20—H12 110.4 
C12—C9—Br1 118.87 (12) O3—C20—H13 110.5 
C13—C9—Br1 117.68 (12) C21—C20—H13 110.5 
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C11—C10—C14 121.37 (14) H12—C20—H13 108.6 
C11—C10—C15 119.94 (13) C20—C21—H15 109.4 
C14—C10—C15 118.38 (13) C20—C21—H14 109.5 
C10—C11—C4 122.22 (14) H15—C21—H14 109.5 
C10—C11—C12 119.51 (14) C20—C21—H16 109.5 
C4—C11—C12 118.23 (14) H15—C21—H16 109.5 
C9—C12—C1 123.73 (15) H14—C21—H16 109.5 
C9—C12—C11 117.97 (14) 
  
 
Torsion Angles 
C15—N1—O1—C17 −0.30 (16) C11—C10—C14—C13 3.4 (2) 
C12—C1—C2—C3 0.5 (3) C15—C10—C14—C13 −170.20 (13) 
C1—C2—C3—C4 −0.2 (3) C6—C5—C14—C10 −176.61 (15) 
C2—C3—C4—C11 −0.2 (2) C6—C5—C14—C13 0.7 (2) 
C14—C5—C6—C7 −0.4 (2) C9—C13—C14—C10 −1.2 (2) 
C5—C6—C7—C8 −0.1 (3) C8—C13—C14—C10 176.87 (14) 
C6—C7—C8—C13 0.3 (3) C9—C13—C14—C5 −178.62 (14) 
C14—C10—C11—C4 179.52 (14) C8—C13—C14—C5 −0.5 (2) 
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C15—C10—C11—C4 −7.0 (2) O1—N1—C15—C16 0.03 (17) 
C14—C10—C11—C12 −2.8 (2) O1—N1—C15—C10 179.54 (12) 
C15—C10—C11—C12 170.64 (13) C11—C10—C15—N1 75.95 (19) 
C3—C4—C11—C10 177.99 (15) C14—C10—C15—N1 −110.38 (17) 
C3—C4—C11—C12 0.3 (2) C11—C10—C15—C16 −104.62 (18) 
C13—C9—C12—C1 179.85 (15) C14—C10—C15—C16 69.0 (2) 
Br1—C9—C12—C1 1.8 (2) N1—C15—C16—C17 0.23 (18) 
C13—C9—C12—C11 2.0 (2) C10—C15—C16—C17 −179.24 (14) 
Br1—C9—C12—C11 −176.09 (11) N1—C15—C16—C19 −178.08 (15) 
C2—C1—C12—C9 −178.22 (16) C10—C15—C16—C19 2.4 (3) 
C2—C1—C12—C11 −0.3 (2) N1—O1—C17—C16 0.45 (17) 
C10—C11—C12—C9 0.2 (2) N1—O1—C17—C18 −179.92 (13) 
C4—C11—C12—C9 177.94 (14) C15—C16—C17—O1 −0.42 (17) 
C10—C11—C12—C1 −177.81 (14) C19—C16—C17—O1 178.01 (14) 
C4—C11—C12—C1 −0.1 (2) C15—C16—C17—C18 −179.96 (17) 
C12—C9—C13—C8 −179.42 (15) C19—C16—C17—C18 −1.5 (3) 
Br1—C9—C13—C8 −1.4 (2) C20—O3—C19—O2 −1.5 (2) 
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C12—C9—C13—C14 −1.4 (2) C20—O3—C19—C16 177.71 (13) 
Br1—C9—C13—C14 176.63 (11) C17—C16—C19—O2 0.7 (3) 
C7—C8—C13—C9 178.02 (16) C15—C16—C19—O2 178.68 (17) 
C7—C8—C13—C14 0.0 (2) C17—C16—C19—O3 −178.56 (14) 
C11—C10—C14—C5 −179.32 (14) C15—C16—C19—O3 −0.6 (2) 
C15—C10—C14—C5 7.1 (2) C19—O3—C20—C21 169.02 (14) 
 
All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using 
the full covariance matrix. The cell esds are taken into account individually in the 
estimation of esds in distances, angles and torsion angles; correlations between esds in 
cell parameters are only used when they are defined by crystal symmetry. An 
approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. 
planes. 
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Chapter 3: Future Work 
 
 As our approach is hypothesis-driven structure based rational drug design, my 
continuing contribution to the AIMs project is to include both mechanistic and synthetic 
studies. In order to advance our understanding of the mechanism by which the AIMs 
exhibit their anti-tumor activity I intend to determine the ability of our lead compounds to 
interact with G4 derived from  telomeric, oncogenic, and mitochondrial DNA.  This data 
will facilitate determination of key interactions that will allow for the design of sequence 
specific quadruplex binding molecules. 
 One method by which we propose to amplify selectivity and inherently efficacy is 
to introduce axial chirality into the AIMs. It is often true that diasteriomers exhibit 
different selectivity and affinity for a given target; the introduction of axial chirality into 
the AIMs will allow for the exploitation of this fact.  Currently we are exploring both 
intramolecular lateral metalations and unsymmetrical halogenations. This work will be 
completed in route to a Ph.D.  Progress will be reported in due course. 
 
